Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesiritide for Insulin Sensitivity in Obese Insulin Resistant Subjects
NCT03234751Phase 1Completed
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nesiritide in insulin resistance (IR) (2 arms), sponsored by AdventHealth Translational Research Institute. Primary endpoint: Insulin Sensitivity measured by hyperinsulinemic euglycemic clamp at 48 hours. Started Jul 2017; status: completed.
02
Drugs
nesiritide
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT03234751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234751.